Table 2: Median intragastric pH during the first 24 and 48 h with different intravenous infusion regimens as a function of CYP2C19 genotype status.

RegimenPeriodsRMIMPM

PlaceboFirst 24 h2.2 (1.3–3.6)2.8 (1.8–3.5)2.4 (1.5–2.9)
First 48 h2.1 (1.5–3.4)2.8 (1.5–3.9)2.4 (1.9–3.3)
FamotidineFirst 24 h4.4 (3.8–4.9)4.1 (3.9–6.5)4.7 (3.7–5.7)
First 48 h4.2 (3.5–4.6)4.0 (3.8–6.1)4.3 (3.6–4.9)
OmeprazoleFirst 24 h3.9 (2.6–4.7)5.8 (4.3–6.3)*6.1 (5.3–7.4)*
First 48 h4.8 (3.2–5.3)6.0 (5.4–6.5)*6.1 (5.7–7.5)*
ConcomitantFirst 24 h4.8 (4.5–5.4)5.8 (5.1–6.4)*5.8 (5.4–6.2)*
First 48 h5.3 (4.7–5.4)5.7 (5.5–6.4)*5.9 (5.5–6.2)*

*: (versus RM).